[go: up one dir, main page]

WO2025043016A3 - A universal vaccine strategy for conferring protection against diverse pathogens - Google Patents

A universal vaccine strategy for conferring protection against diverse pathogens Download PDF

Info

Publication number
WO2025043016A3
WO2025043016A3 PCT/US2024/043282 US2024043282W WO2025043016A3 WO 2025043016 A3 WO2025043016 A3 WO 2025043016A3 US 2024043282 W US2024043282 W US 2024043282W WO 2025043016 A3 WO2025043016 A3 WO 2025043016A3
Authority
WO
WIPO (PCT)
Prior art keywords
protection against
weeks
conferring protection
vaccine strategy
against diverse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/043282
Other languages
French (fr)
Other versions
WO2025043016A2 (en
Inventor
Bali Pulendran
Audrey Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2025043016A2 publication Critical patent/WO2025043016A2/en
Publication of WO2025043016A3 publication Critical patent/WO2025043016A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions and methods are provided for immunizing an individual or population of individuals to generate an immune response that protects against pathogen infection in an antigen-agnostic manner. The protective antigen-agnostic immune response is active for a period of time following immunization, from about 7 days, 10 days, 14 days following immunization, and may be active for at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
PCT/US2024/043282 2023-08-21 2024-08-21 A universal vaccine strategy for conferring protection against diverse pathogens Pending WO2025043016A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363533893P 2023-08-21 2023-08-21
US63/533,893 2023-08-21

Publications (2)

Publication Number Publication Date
WO2025043016A2 WO2025043016A2 (en) 2025-02-27
WO2025043016A3 true WO2025043016A3 (en) 2025-04-17

Family

ID=94732787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/043282 Pending WO2025043016A2 (en) 2023-08-21 2024-08-21 A universal vaccine strategy for conferring protection against diverse pathogens

Country Status (1)

Country Link
WO (1) WO2025043016A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160303046A1 (en) * 2010-03-19 2016-10-20 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20170370933A1 (en) * 2013-10-25 2017-12-28 Nodality, Inc. Methods and compositions for immunomodulation
US20190142935A1 (en) * 2016-05-16 2019-05-16 Infectious Disease Research Institute Formulation Containing TLR Agonist and Methods of Use
US20200188511A1 (en) * 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160303046A1 (en) * 2010-03-19 2016-10-20 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20170370933A1 (en) * 2013-10-25 2017-12-28 Nodality, Inc. Methods and compositions for immunomodulation
US20190142935A1 (en) * 2016-05-16 2019-05-16 Infectious Disease Research Institute Formulation Containing TLR Agonist and Methods of Use
US20200188511A1 (en) * 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines

Also Published As

Publication number Publication date
WO2025043016A2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
Pilz et al. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity
WO2003009812A3 (en) Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CA2311492A1 (en) Vaccines with an ltb adjuvant
FI3471760T3 (en) Novel immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
MXPA02004627A (en) Vaccines for mycoplasma bovis.
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
WO2001060849A3 (en) Cold-adapted equine influenza viruses
EP4295862A3 (en) Coronavirus vaccine
MX2023012368A (en) Virus vaccine.
WO2025043016A3 (en) A universal vaccine strategy for conferring protection against diverse pathogens
GB2458057A (en) Francisella strain for live vaccine
EP4324832A3 (en) Immunomodulatory compounds and use thereof for the treatment and/or prevention of infectious diseases
WO2021207281A3 (en) Vaccines, adjuvants, and methods of generating an immune response
HUP0303878A2 (en) Smallpox vaccine
JP2005503126A5 (en)
WO2004084935A3 (en) Francisella strain for live vaccine
MX2023011640A (en) Staphylococcus aureus vaccine compositions.
ES2445016R1 (en) VACCINE FOR THE TREATMENT / PREVENTION OF ESCUTICOCILIATOSIS IN FISH
MX2023003198A (en) Attenuated isolate of infectious bronchitis virus strain dmv1639.
WO2003049670A3 (en) Adjuvant formulations for bacterial and virus vaccines and method of making same
Starnino et al. Molecular analysis of two novel Neisseria gonorrhoeae virulent components: the macrophage infectivity potentiator and the outer membrane protein A.
WO2023014983A3 (en) Rabbit haemorrhagic disease virus (rhdv) vaccines
WO2024036135A3 (en) Vaccines for the treatment and prevention of seasonal and emerging infections
WO2024081953A3 (en) Vaccines and antibodies for the treatment and prevention of microbial infections
MX2025012624A (en) Oligonucleotides for use in modulating immune responses against hepatitis b viral infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24857255

Country of ref document: EP

Kind code of ref document: A2